Keyphrases
Non-vitamin K Antagonist Oral Anticoagulants
100%
GLORIA-AF
100%
Antithrombotic Therapy
85%
Vitamin K Antagonists
85%
North America
57%
Europe
28%
Newly Diagnosed
28%
Baseline Data
28%
Antiplatelet Drugs
28%
Non-valvular Atrial Fibrillation
28%
Asia
28%
International Registry
28%
CHA2DS2-VASc
28%
Type 1 Diabetes Mellitus (T1DM)
14%
Hypertension
14%
Vascular Disease
14%
Middle East
14%
Stroke Risk
14%
Congestive Heart Failure
14%
Atrial Fibrillation
14%
Baseline Characteristics
14%
East Africa
14%
Descriptive Statistics
14%
Dabigatran
14%
Latin America (LATAM)
14%
Sectional Analysis
14%
Antiplatelet Agents
14%
Medical Outcomes
14%
Undertreated
14%
Moderate Risk
14%
Concomitant Medications
14%
Treatment Patterns
14%
Acetylsalicylic Acid
14%
Concomitant Diseases
14%
Previous Stroke
14%
Antiplatelet Treatment
14%
Oral Anticoagulants
14%
Anticoagulant Use
14%
High Stroke Risk
14%
Medicine and Dentistry
Antithrombotic
100%
Vitamin K Antagonist
42%
Atrial Fibrillation
21%
Apoplexy
21%
Antiplatelet Drug
21%
CHA2DS2-VASc Score
14%
Diseases
7%
Diabetes Mellitus
7%
Drug Therapy
7%
Antiplatelet
7%
Congestive Heart Failure
7%
Acetylsalicylic Acid
7%
Dabigatran
7%
Cross Sectional Study
7%
Vascular Disease
7%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Antivitamin K
42%
Antithrombocytic Agent
21%
Cerebrovascular Accident
21%
Atrial Fibrillation
21%
Cross Sectional Study
7%
Antiplatelet
7%
Congestive Heart Failure
7%
Acetylsalicylic Acid
7%
Disease
7%
Diabetes Mellitus
7%
Vascular Disease
7%
Dabigatran
7%